Peter Albers, MD, presented “Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50)” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Albers, Peter. “Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50).” October 8, 2024. Accessed Dec 2024. https://grandroundsinurology.com/update-on-probase-trial-baseline-psa-in-young-men-aged-45-and-50-2/
Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50) – Summary
Peter Albers, MD, highlights key findings from the ongoing PROBASE screening trial, which began in 2014 to evaluate prostate cancer detection in younger men. The trial focuses on identifying low-risk individuals to minimize harm while more effectively targeting high-risk groups.
In this 12-minute presentation, Dr. Albers shares data from PROBASE showing that identifying a baseline PSA low-risk cutoff PSA value of less than 1.5 ng/mL safely reduces unnecessary testing for five years. The strategy could reduce overtesting by broadening the low-risk group definition while ensuring early detection of clinically significant cancers.
Albers shares that MRI also plays a critical role, especially in refining high-risk group identification. PROBASE findings suggest strict biopsy criteria, such as PIRADS 4 thresholds, enhance specificity and reduce unnecessary procedures.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Peter Albers, MD, is a Board Member of the European Cancer Organization and Professor of Urology and Chairman of the Department of Urology, Heinrich-Heine-University Düsseldorf, Germany. From 2018 to 2022, he served as Medical Director of the CIO Düsseldorf, Comprehensive Cancer Center at the University Hospital Düsseldorf. In January 2020 he was double appointed Division Head of the newly established Division “Personalized Early Detection of Prostate Cancer” in the National Cancer Prevention Center of the German Cancer Research Center (DKFZ) in Heidelberg.
His special research interests are the development of new risk-adapted screening programs for prostate cancer and clinical research in testicular cancer.
